Cargando…

Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve endothelial dysfunction and reduce cardiovascular events in individuals with type 2 diabetes (T2D). Proprotein convertase subtilisin/kexin 9 (PCSK9i) inhibitors reduce cardiovascular events in high-risk patients. Whether the addi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sposito, Andrei C., Breder, Ikaro, Barreto, Joaquim, Breder, Jessica, Bonilha, Isabella, Lima, Marcus, Oliveira, Alessandra, Wolf, Vaneza, Luchiari, Beatriz, do Carmo, Helison R., Munhoz, Daniel, Oliveira, Daniela, Coelho-Filho, Otavio R., Coelho, Otavio R., Matos-Souza, Jose Roberto, Moura, Filipe A., de Carvalho, Luiz Sergio F., Nadruz, Wilson, Quinaglia, Thiago, Kimura-Medorima, Sheila T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356512/ https://www.ncbi.nlm.nih.gov/pubmed/35933413 http://dx.doi.org/10.1186/s12933-022-01584-8

Ejemplares similares

Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial
por: Breder, Ikaro, et al.
Publicado: (2020)

Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis
por: Barreto, Joaquim, et al.
Publicado: (2022)

Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
por: Sposito, Andrei C., et al.
Publicado: (2021)

Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial
por: Cintra, Riobaldo M. R., et al.
Publicado: (2019)

Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
por: Wolf, Vaneza Lira W., et al.
Publicado: (2021)

Coronavirus disease-19: The multi-level, multi-faceted vasculopathy
por: Quinaglia, Thiago, et al.
Publicado: (2021)

Very low HDL levels: clinical assessment and management
por: Bonilha, Isabella, et al.
Publicado: (2023)

Omega-3 intake is associated with attenuated inflammatory response and cardiac remodeling after myocardial infarction
por: Campos-Staffico, Alessandra M., et al.
Publicado: (2019)

The role of SGLT2i in attenuating residual cardiovascular risk through blood pressure-lowering: mechanistic insights and perspectives
por: Barreto, Joaquim, et al.
Publicado: (2023)

Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model
por: Nogueira, Ana Claudia Cavalcante, et al.
Publicado: (2023)

The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus
por: Bonilha, Isabella, et al.
Publicado: (2021)

Cardiac Sympathetic Activity and the Neuro-Humoral Theory on Heart Failure with Reduced Ejection Fraction: Have We Learned Enough?
por: Silva, Thiago Quinaglia A. C., et al.
Publicado: (2018)

Cardiac magnetic resonance assessment of right ventricular remodeling after anthracycline therapy
por: de Souza, Thiago Ferreira, et al.
Publicado: (2021)

P-wave duration is a predictor for long-term mortality in post-CABG patients
por: Kimura-Medorima, Sheila Tatsumi, et al.
Publicado: (2018)

Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and design
por: Barreto, Joaquim, et al.
Publicado: (2023)

Diabetic and non-diabetic patients in the intensive care unit: morbidity and mortality
por: Barros, Antonio Carlos, et al.
Publicado: (2015)

Characterization of peri-infarct zone by CMR is a robust predictor of major adverse events and is strongly associated with systemic inflammatory response post-myocardial infarction
por: Sposito, Andrei, et al.
Publicado: (2011)

Noninvasive imaging assessment of rehabilitation therapy in heart failure with preserved and reduced left ventricular ejection fraction (IMAGING-REHAB-HF): design and rationale
por: Cardoso, Fernando Bianchini, et al.
Publicado: (2019)

Informative graphing of continuous safety variables relative to normal reference limits
por: Breder, Christopher D.
Publicado: (2018)

Cystatin C as a Candidate Biomarker of Cardiovascular Outcomes: Too Near, but too Far from Reality
por: de Carvalho, Luiz Sérgio F., et al.
Publicado: (2018)

Statin Short-term Inhibition of Insulin Sensitivity and Secretion During Acute Phase of ST-Elevation Myocardial Infarction
por: Sposito, Andrei C., et al.
Publicado: (2019)

Aspirin in primary prevention and the risk of heart failure: a systematic review and meta‐analysis of controlled trials
por: de Oliveira, Ana Beatrice Magalhães, et al.
Publicado: (2022)

Prognostic role of renal replacement therapy among hospitalized patients with heart failure in the Brazilian national public health system
por: Coy-Canguçu, Andréa, et al.
Publicado: (2023)

CSII treatment as an option in high-risk pregnant patients with type 1 diabetes
por: Breder, Íkaro Soares Santos, et al.
Publicado: (2015)

O Impacto da Educação na Mortalidade por Todas as Causas após Infarto do Miocárdio com Supradesnivelamento do Segmento ST (IAMCSST): Resultados do Brasília Heart Study
por: Barreto, Joaquim, et al.
Publicado: (2021)

Glucose-Lowering and the Risk of Cardiovascular Events With Antidiabetic Therapies: A Systematic Review and Additive-Effects Network Meta-Analysis
por: de Carvalho, Luiz Sergio Fernandes, et al.
Publicado: (2022)

Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes
por: Sarak, Bradley, et al.
Publicado: (2021)

Diffuse Myocardial Fibrosis and Cardiomyocyte Diameter Are Associated With Heart Failure Symptoms in Chagas Cardiomyopathy
por: Nardi Gemme, Cristiane, et al.
Publicado: (2022)

Effects of Evolocumab on Cardiovascular Events
por: Mikhail, Nasser
Publicado: (2017)

Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia
por: Lee, Timothy, et al.
Publicado: (2019)

Synthesis of 1,3‐Dioxan‐2‐ones by Photo‐Aerobic Selenium‐π‐Acid Multicatalysis
por: Müller, Kilian A., et al.
Publicado: (2022)

Relationship Between Circulating MicroRNAs and Left Ventricular Hypertrophy in Hypertensive Patients
por: Lopes, Elisangela C. P., et al.
Publicado: (2022)

Impact of Hypertension History and Blood Pressure at Presentation on Cardiac Remodeling and Mortality in Aortic Dissection
por: Oliveira, Matheus F. R. A., et al.
Publicado: (2022)

Left Ventricular Concentric Geometric Patterns Are Associated With Worse Prognosis Among Patients With Type‐A Aortic Dissection
por: Rocha, Walter E. M., et al.
Publicado: (2021)

Defective Allele of the Neuronal Nitric Oxide Synthase Gene Increases Insulin Resistance During Acute Phase of Myocardial Infarction
por: Nóbrega, Otávio T, et al.
Publicado: (2021)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

Association of Circulating miR-145-5p and miR-let7c and Atherosclerotic Plaques in Hypertensive Patients
por: Minin, Eduarda O. Z., et al.
Publicado: (2021)

Reference intervals for serum immunoglobulin A levels in Brazilian children aged 1 to 10 years: a population-based study
por: Assis, Sandra Breder, et al.
Publicado: (2023)

Sickle-cell Anemia and Latent Diastolic Dysfunction: Echocardiographic Alterations
por: Fattori, André, et al.
Publicado: (2015)

Patterns of use and impact of standardised MedDRA query analyses on the safety evaluation and review of new drug and biologics license applications
por: Chang, Lin-Chau, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7pog92if3997kpd7ia03m31di0